Skip to main content

Table 5 Risk factors for CLL

From: Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?

Variables

Univariate

Multivariate

OR

95% CI

p

OR

95% CI

p

Gender

 Female

ref

     

 Male

3.13

1.27–7.67

0.013*

   

WBC

1.61

1.29–2.00

< 0.001*

1.58

1.26–2.01

< 0.001*

Neutrophil

1.13

0.93–1.37

0.229

   

Platelet

0.98

0.97–0.98

0.026*

   

ELABELA

1.31

1.13–1.52

< 0.001*

1.38

1.17–1.63

< 0.001*

    

Nagelkerke R2 = 0.849; p < 0.001*

  1. Abbreviations: OR Odds ratio, CI Confidence intervals
  2. * P < 0.05 indicates statistical significance
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us